Total Payments
$37,763
2024 Payments
$7,108
Companies
28
Transactions
81
Medicare Patients
617
Medicare Billing
$116,487
Payment Breakdown by Category
Consulting$16,914 (44.8%)
Research$10,773 (28.5%)
Other$4,220 (11.2%)
Food & Beverage$4,133 (10.9%)
Travel$1,724 (4.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $16,914 | 9 | 44.8% |
| Unspecified | $10,773 | 3 | 28.5% |
| Food and Beverage | $4,133 | 58 | 10.9% |
| Honoraria | $2,400 | 1 | 6.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,820 | 1 | 4.8% |
| Travel and Lodging | $1,724 | 9 | 4.6% |
Payments by Type
General
$26,990
78 transactions
Research
$10,773
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $13,541 | 7 | $0 (2019) |
| Kyowa Kirin, Inc. | $5,620 | 7 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $3,806 | 2 | $0 (2024) |
| Genmab U.S., Inc. | $2,908 | 11 | $0 (2023) |
| Incyte Corporation | $2,505 | 2 | $0 (2024) |
| ADC Therapeutics America, Inc. | $2,400 | 1 | $0 (2021) |
| MorphoSys, US Inc. | $1,935 | 2 | $0 (2023) |
| PFIZER INC. | $1,124 | 2 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $870.93 | 5 | $0 (2024) |
| Kite Pharma, Inc. | $623.47 | 8 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,108 | 13 | Incyte Corporation ($2,398) |
| 2023 | $5,152 | 20 | Genmab U.S., Inc. ($2,908) |
| 2022 | $2,038 | 10 | MorphoSys, US Inc. ($1,845) |
| 2021 | $2,583 | 3 | ADC Therapeutics America, Inc. ($2,400) |
| 2020 | $2,913 | 4 | Kyowa Kirin, Inc. ($2,700) |
| 2019 | $4,341 | 17 | Celgene Corporation ($2,781) |
| 2018 | $11,788 | 9 | Celgene Corporation ($9,176) |
| 2017 | $1,840 | 5 | Celgene Corporation ($1,584) |
All Payment Transactions
81 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | PFIZER INC. | ADCETRIS (Biological) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 09/13/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Travel and Lodging | Cash or cash equivalent | $251.85 | General |
| Category: Oncology | ||||||
| 09/06/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| 08/17/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Travel and Lodging | In-kind items and services | $335.00 | General |
| Category: Oncology | ||||||
| 08/17/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $51.92 | General |
| Category: Oncology | ||||||
| 08/17/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $47.16 | General |
| Category: Oncology | ||||||
| 08/16/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Travel and Lodging | In-kind items and services | $185.00 | General |
| Category: Oncology | ||||||
| 04/29/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $159.64 | General |
| Category: ONCOLOGY | ||||||
| 04/28/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $214.51 | General |
| 04/22/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $129.95 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2024 | PFIZER INC. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $123.99 | General |
| Category: Oncology | ||||||
| 01/22/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,076.00 | General |
| 10/20/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,820.00 | General |
| Category: Oncology | ||||||
| 10/20/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | Cash or cash equivalent | $362.88 | General |
| Category: Oncology | ||||||
| 10/19/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | Cash or cash equivalent | $399.00 | General |
| Category: Oncology | ||||||
| 10/19/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | Cash or cash equivalent | $125.61 | General |
| Category: Oncology | ||||||
| 10/19/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | Cash or cash equivalent | $81.75 | General |
| Category: Oncology | ||||||
| 10/19/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | Cash or cash equivalent | $69.28 | General |
| Category: Oncology | ||||||
| 10/19/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | Cash or cash equivalent | $27.80 | General |
| Category: Oncology | ||||||
| 10/19/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | Cash or cash equivalent | $12.14 | General |
| Category: Oncology | ||||||
| 10/19/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | Cash or cash equivalent | $4.75 | General |
| Category: Oncology | ||||||
| 10/19/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | Cash or cash equivalent | $2.40 | General |
| Category: Oncology | ||||||
| 10/19/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | Cash or cash equivalent | $1.90 | General |
| Category: Oncology | ||||||
| 10/04/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,730.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-486-AML-002 - A Phase 1/2 Dose and Schedule Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Azacitidine (CC-486) in Subjects with Acute Myelogenous Leukemia and | Celgene Corporation | $9,176 | 1 |
| CC-486-AML-002 | Celgene Corporation | $1,488 | 1 |
| A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) | Kite Pharma, Inc. | $108.81 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 109 | 421 | $94,805 | $42,523 |
| 2022 | 5 | 182 | 208 | $39,715 | $14,980 |
| 2021 | 3 | 223 | 368 | $82,068 | $42,244 |
| 2020 | 4 | 103 | 253 | $55,080 | $16,740 |
Total Patients
617
Total Services
1,250
Medicare Billing
$116,487
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 270 | $57,780 | $25,296 | 43.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 29 | 79 | $14,773 | $7,626 | 51.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 25 | 25 | $9,075 | $4,211 | 46.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 25 | $8,975 | $3,414 | 38.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 16 | 22 | $4,202 | $1,976 | 47.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 82 | 105 | $19,635 | $5,783 | 29.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 48 | 51 | $6,426 | $3,256 | 50.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 20 | 20 | $7,260 | $3,131 | 43.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $5,026 | $2,200 | 43.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 18 | 18 | $1,368 | $609.44 | 44.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 148 | 292 | $54,604 | $29,373 | 53.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 45 | 45 | $16,335 | $7,923 | 48.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 30 | 31 | $11,129 | $4,948 | 44.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 66 | 169 | $32,955 | $9,560 | 29.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 14 | 61 | $15,555 | $4,904 | 31.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 12 | 12 | $4,920 | $1,641 | 33.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 11 | 11 | $1,650 | $635.68 | 38.5% |
About Dr. Basem William, MD
Dr. Basem William, MD is a Hospitalist healthcare provider based in Marion, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952416505.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Basem William, MD has received a total of $37,763 in payments from pharmaceutical and medical device companies, with $7,108 received in 2024. These payments were reported across 81 transactions from 28 companies. The most common payment nature is "Consulting Fee" ($16,914).
As a Medicare-enrolled provider, William has provided services to 617 Medicare beneficiaries, totaling 1,250 services with total Medicare billing of $116,487. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Hospitalist
- Other Specialties Hematology & Oncology
- Location Marion, OH
- Active Since 08/21/2006
- Last Updated 12/15/2021
- Taxonomy Code 208M00000X
- Entity Type Individual
- NPI Number 1952416505
Products in Payments
- CC-486 (Drug) $10,664
- POTELIGEO (Drug) $5,512
- Epkinly (Drug) $2,908
- JCAR017 (Drug) $2,781
- MONJUVI (Drug) $2,043
- ADCETRIS (Biological) $1,475
- XPOVIO (Drug) $870.93
- Yescarta (Drug) $514.66
- clonoSEQ (Device) $490.20
- KYMRIAH (Biological) $282.12
- CALQUENCE (Drug) $135.00
- EPKINLY (Drug) $124.44
- SANCUSO (Drug) $107.68
- Doptelet (Drug) $95.42
- UVADEX (METHOXSALEN) STERILE SOLUTION (Drug) $82.65
- SGN-CD33A (Biological) $70.09
- ONPATTRO (Drug) $60.18
- DEFITELIO (Drug) $48.39
- Defitelio (Drug) $44.17
- NINLARO (Drug) $30.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hospitalist Doctors in Marion
Dr. James Alexander, Md, MD
Hospitalist — Payments: $15,732
Hospitalist $15,732
Dr. Gladstone Tucker, Md, MD
Hospitalist — Payments: $969.83
Hospitalist $969.83
Dhiraj Shah, Md, MD
Hospitalist — Payments: $885.58
Hospitalist $885.58
Imran Ehsan, Md, MD
Hospitalist — Payments: $588.88
Hospitalist $588.88
Amber Banks
Hospitalist — Payments: $307.22
Hospitalist $307.22
Eduardo Avena Arevalo, Md, MD
Hospitalist — Payments: $148.57
Hospitalist $148.57